Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Cystatin C: A Candidate Biomarker for Amyotrophic Lateral Sclerosis

Wilson, ME and Boumaza, I and Lacomis, D and Bowser, R (2010) Cystatin C: A Candidate Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE, 5 (12).

Published Version
Available under License : See the attached license file.

Download (336kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Amyotrophic lateral sclerosis (ALS) is a fatal neurologic disease characterized by progressive motor neuron degeneration. Clinical disease management is hindered by both a lengthy diagnostic process and the absence of effective treatments. Reliable panels of diagnostic, surrogate, and prognostic biomarkers are needed to accelerate disease diagnosis and expedite drug development. The cysteine protease inhibitor cystatin C has recently gained interest as a candidate diagnostic biomarker for ALS, but further studies are required to fully characterize its biomarker utility. We used quantitative enzymelinked immunosorbent assay (ELISA) to assess initial and longitudinal cerebrospinal fluid (CSF) and plasma cystatin C levels in 104 ALS patients and controls. Cystatin C levels in ALS patients were significantly elevated in plasma and reduced in CSF compared to healthy controls, but did not differ significantly from neurologic disease controls. In addition, the direction of longitudinal change in CSF cystatin C levels correlated to the rate of ALS disease progression, and initial CSF cystatin C levels were predictive of patient survival, suggesting that cystatin C may function as a surrogate marker of disease progression and survival. These data verify prior results for reduced cystatin C levels in the CSF of ALS patients, identify increased cystatin C levels in the plasma of ALS patients, and reveal correlations between CSF cystatin C levels to both ALS disease progression and patient survival. © 2010 Wilson et al.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Wilson, ME
Boumaza, I
Lacomis, Dlacomisd@pitt.eduLACOMISD
Bowser, R
ContributionContributors NameEmailPitt UsernameORCID
Date: 20 December 2010
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 5
Number: 12
DOI or Unique Handle: 10.1371/journal.pone.0015133
Schools and Programs: School of Medicine > Neurology
School of Medicine > Pathology
Refereed: Yes
MeSH Headings: Amyotrophic Lateral Sclerosis--blood; Amyotrophic Lateral Sclerosis--mortality; Biological Markers; Cystatin C--blood; Cystatin C--diagnostic use; Disease Progression; Enzyme-Linked Immunosorbent Assay--methods; Female; Humans; Male; Mass Spectrometry--methods; Middle Aged; Prognosis; Proteomics--methods; Regression Analysis; Treatment Outcome
Other ID: NLM PMC3000338
PubMed Central ID: PMC3000338
PubMed ID: 21151566
Date Deposited: 25 Aug 2012 16:45
Last Modified: 02 Feb 2019 14:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item